Sarah Mundt is Group Leader for Neuroimmunology at the Department of Neurology, University Hospital Zurich, Switzerland. Her research combines single-cell profiling, functional proteomics, and conditional gene targeting with preclinical models of multiple sclerosis (MS) to dissect neuroimmune interactions in CNS inflammation.

Dr. Mundt received her PhD in 2016 from the University of Konstanz, Germany, where she uncovered an immunoregulatory role of the immunoproteasome in CNS neuroinflammation (EMBO Molecular Medicine, 2014; European Journal of Immunology, 2015). She then joined the University of Zurich as a postdoctoral fellow with Prof. Burkhard Becher, identifying dendritic cells as critical CNS antigen-presenting cells that locally reactivate encephalitogenic T cells (Science Immunology, 2019; Trends in Neurosciences, 2019).

In 2020, supported by an SNSF Ambizione fellowship, Dr. Mundt established her independent group at the Institute of Experimental Immunology, University of Zurich, and later joined the Department of Neurology at the University Hospital Zurich. Her team has since revealed a tissue-protective role of IL-12 in the neuroectoderm and skin keratinocytes (Nature Neuroscience, 2023; Science Immunology, 2021), demonstrated that ROS-producing monocyte-derived cells—but not microglia—drive oxidative damage in neuroinflammation (bioRxiv, 2024), and identified maladaptive lipid-associated macrophages as a hallmark of progressive neuroinflammation (bioRxiv, 2025).

Her work has helped redefine the roles of mononuclear phagocytes in neuroinflammation, proposing a new conceptual framework (Neuron, 2022; Trends in Immunology, 2024). In 2025, she received the Sobek Young Investigator Award in recognition of her contributions to MS research.